



PRESS RELEASE PRESS RELEASE

XLER8TR ANNOUNCES DEVELOPMENT OF 'XAMN' THE UNIQUE TOOLBOX ACCESSING OVER 15,000 PEER REVIEWED AND FUNDED EARLY STAGE PROJECTS.

Xler8tr announced today that it is beta testing its unique toolbox 'Xamn' (pronounced 'examine').

It is maybe not surprising that in-house VC funds have not delivered diversity to the pharma life sciences pipeline in the way originally envisaged, and, the locus of External Innovations is, with one or two forward looking exceptions, firmly at the incubator stage. Although everyone acknowledges that incubator programs do need feeders there has been a historic barrier to entry at this earlier stage.

The Xler8tr program is focused upon this very early stage, pre POC but interesting science. The Xler8tr model is unique in that it focuses solely on advancing the commercials while our pharma sponsors mentors the science. This gives us the competitive advantage of being science agnostic and not constrained by in-house expertise.

Although the potential for deals is considerably larger at this earlier pre-incubation stage, it is far less well mapped. It is this agnosticism however that makes Xler8tr the wrong organisation to scout for potential opportunities. Nevertheless we recognised that there was a need to build a toolbox for clients to start to map the territory.

Xler8tr's total commitment to both our pharma clients and to this segment led us to the development of Xamn. Xamn is an extremely powerful tool which can be used by our client base to identify those peer reviewed projects within their fields of interest and then use needlepoint accuracy to filter out the white noise.

About Xler8tr

The Cambridge based pharmaceutical / life sciences accelerator with strategic partnerships with leading global advisory businesses advances the commercials of very early stage (pre POC) science through incorporation creating independent and transportable IT, legal and management accounting infrastructure vested with IP. Xler8tr creates a digital presence and initial branding. At the end of the 6 month course prospects articulate their commercialisation plans with supporting data room to attract next stage dilutive and non-dilutive funding.



PRESS RELEASE PRESS RELEASE

With Xamn once the smaller and relevant dataset has been collated a substantial amount of detail about the science can be extracted, enough to give clients a thorough and detailed snapshot of the directly relevant landscape and their need for funding.

Using Xamn from Xler8tr allows pharma, maybe for the first time, to be extremely pro-active and target those projects that they find interesting and create new independent channels to broaden their pipelines rather than be reliant on referrals.

Xamn is currently in beta testing. Xler8tr expects initial and limited release of the Xamn toolbox in August.

20 July 2017

About Xler8tr

The Cambridge based pharmaceutical / life sciences accelerator with strategic partnerships with leading global advisory businesses advances the commercials of very early stage (pre POC) science through incorporation creating independent and transportable IT, legal and management accounting infrastructure vested with IP. Xler8tr creates a digital presence and initial branding. At the end of the 6 month course prospects articulate their commercialisation plans with supporting data room to attract next stage dilutive and non-dilutive funding.